Please set your featured image

Oxford, UK – 23 February 2011. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine , is discussing recent developments in biomarker discovery at this year’s CHI International Molecular Medicine Tri-Conference (Tri-Con) in San Francisco, USA (23-25 th February). As well as presenting its genomic and proteomic diagnostic biomarker services at Tri-Con booth 626, OGT gave a talk at the CHI Early Oncology Partnering Showcase immediately before the Tri-Con event. The talk, entitled “Development of a panel of biomarkers for improved detection of prostate cancer”, was presented by OGT’s head of Business Development Biomarker Discovery, Will Colón. It described the use of OGT’s unique “functional protein” array platform to identify a panel of autoantibody biomarkers that can detect prostate cancer with greater sensitivity and specificity than current tests. OGT has also produced a new brochure outlining the benefits of its diagnostic biomarker technology, which is available at the OGT booth (# 626), together with OGT representatives, who are on hand for more in-depth discussion.

Ben Broughton, Bodle Technologies

“Thank you very much for all the help with signage and room set-up. The meeting ran very smoothly and the Blenheim Room makes a very nice location.”

Jim Watts, Head, Product Engineering, Oxford PV

I found the RSC event hosted at the Begbroke Science Park both extremely informative and a great opportunity for networking with other local scientists. I hadn’t appreciated the extent to which the RSC are supporting small businesses, from the high-profile publicity associated with winning one of their annual awards, to the more direct benefit of their Enterprise Plus scheme (where undergraduate students are provided grants to fulfil industrial placements). Overall I found it to be a great success and an event worth attending. Thank you RSC and Begbroke Science Park.